Shares of Burning Rock Biotech Limited (NASDAQ: BNR) plummeted by 5.31% on Thursday, September 27, 2024, following the resignation of its Chief Financial Officer and board director, Leo Li, for personal reasons.
According to the company's announcement, Mr. Li's resignation was effective September 27, 2024, and was not due to any disagreement with the Board, the company, or its affiliates regarding operations, policies, or practices. Burning Rock stated that Mr. Li confirmed he has no claims against the company.
In light of Mr. Li's departure, Xiaozhi Hu, the senior director in finance, will oversee the company's financial operations, financial reporting, and related matters. Ms. Hu will report directly to Yusheng Han, the chairman of the board and chief executive officer. Mr. Han expressed gratitude for Mr. Li's contributions during his tenure, particularly during the company's initial public offering and subsequent business development projects.
Burning Rock Biotech Limited, based in Guangzhou, China, is focused on the application of next-generation sequencing (NGS) technology in precision oncology. The company's business includes NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has progressed into the clinical validation stage.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。